Stroke Prevention Trial Reveals High-Risk Patients Without Stents Implanted Had Fewer Second Strokes

Saturday, September 10th, 2011

Specialists in Stony Brook University School of Medicine's Departments of Neurology and Neurological Surgery took part in a nationwide National Institutes of Health (NIH)-sponsored clinical trial, the results of which showed that patients at high risk for a second stroke had a lower risk of stroke and death when treated ...

Discrimination In The NIH: White Research Gets More Grants Than Black

Friday, August 19th, 2011

In what the National Institutes of Health (NIH) deem "unacceptable," it has been discovered that black researchers are 10 percentage points less likely than their white counterparts to receive research grants from the same organization. Blacks were less likely to receive the grants, regardless of education, training, citizenship, country ...

How Toxicity Of Fatty Acids Links Obesity And Diabetes

Sunday, July 24th, 2011

Though it generally is known that obesity dramatically increases the risk for type 2 diabetes, the biological mechanisms for that connection still are unclear. Backed by several grants from the National Institutes of Health (NIH), James Granneman, Ph.D., professor of psychiatry and behavioral neurosciences and pathology in Wayne State University's ...

University Of Pittsburgh Receives $67.3 Million To Translate Science Into Therapies

Tuesday, July 19th, 2011

A University of Pittsburgh institute aimed at accelerating the pace of translating science into real-life treatments for patients has received $67.3 million from the National Institutes of Health (NIH) to expand its work over the next five years. Pitt's Clinical and Translational Science Institute (CTSI) is among 10 institutes nationwide ...

P2D Bioscience Lead ADHD Drug Demonstrates Efficacy In Preclinical Testing

Thursday, April 14th, 2011

P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of ADHD in preclinical ADHD models. The independently conducted studies were funded by a grant from the National Institutes of Health (NIH). ...